Zenas BioPharma (NASDAQ:ZBIO) CEO Buys $819,000.00 in Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was purchased at an average price of $16.38 per share, with a total value of $819,000.00. Following the completion of the purchase, the chief executive officer directly owned 316,155 shares in the company, valued at $5,178,618.90. The trade was a 18.79% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Zenas BioPharma Stock Performance

Shares of Zenas BioPharma stock traded down $0.33 on Friday, hitting $16.08. The stock had a trading volume of 529,200 shares, compared to its average volume of 981,324. The business’s 50 day moving average is $34.94 and its two-hundred day moving average is $24.01. The stock has a market cap of $863.17 million, a price-to-earnings ratio of -2.27 and a beta of -1.45. Zenas BioPharma, Inc. has a twelve month low of $5.83 and a twelve month high of $44.60. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Wall Street Analysts Forecast Growth

ZBIO has been the subject of several research analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research report on Tuesday. Evercore ISI initiated coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a report on Tuesday, December 16th. Citigroup increased their target price on Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Finally, Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zenas BioPharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Hedge Funds Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP grew its position in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Zenas BioPharma in the third quarter worth about $30,000. BNP Paribas Financial Markets increased its holdings in Zenas BioPharma by 120.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Zenas BioPharma by 41.2% in the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after acquiring an additional 2,679 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Zenas BioPharma in the 2nd quarter worth approximately $118,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.